

PTO/SB/21 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/519,824
Filing Date	December 30, 2004
First Named Inventor	Martina BOEHM
Group Art Unit	
Examiner Name	Not assigned
Attorney Docket Number	02/104 DBM

Total Number of Pages in This Submission

ENCLOSURES (check all that apply)

- | | | |
|--|--|---|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment / Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request

Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement
<input type="checkbox"/> Response to Missing Parts/Incomplete Application
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer

<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____

Remarks:
Postcard Receipt
Search Rpt; 22 references | <input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communications to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information

<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<div></div> |
|--|--|---|

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name	ProPat, L.L.C. 425-C South Sharon Amity Road Charlotte, NC 28211-2841
Signature	<i>Cathy Moore</i>
Date	January 24, 2005

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Claire Wygand		
Signature	<i>Claire Wygand</i>	Date	1/24/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



DT03 Rec'd PCTO 26 JAN 2005

PCT #3

Attorney Docket No.: 02/104 DBM
Customer No. 38263

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK
OFFICE PATENT OPERATIONS

In re: Martina BOEHM *et al.*

Application No.: 10/519,824

Filing Date: December 30, 2004

For: **Method for detecting the von Willebrand factor-cleaving protease activity of ADAMTS-13**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-145

Charlotte, North Carolina
January 24, 2005

Dear Sirs:

Pursuant to 37 CFR §§ 1.56 and 1.97 *et seq.*, Applicant hereby submits the attached Forms PTO/SB/08A; PTO/SB/08B and the references listed thereon. The relevancy of each reference is disclosed in the attached International Search Report of the WO-Publication 2004/005451A2, which is the counterpart PCT application to the above-referenced application.

This submission does not represent an admission that each or all of the listed documents are material or constitute "prior art." Applicant respectfully requests that each reference be reviewed and made of record in the instant application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 50-2193.

Respectfully submitted,

Cathy Moore

Cathy R. Moore
Reg. No. 45,764
ProPat, L.L.C.
425-C South Sharon Amity Road
Charlotte, North Carolina 28211-2841
Telephone (704) 365-4881


O I P E J C I T S
JAN 26 2005

PTO/SB/08A		Complete if Known	
Substitute for Form 1449A/PTO		Application No.	10/519,824
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	December 30, 2004
		First Named Inventor	Martina BOEHM
		Group Art Unit	
		Examiner Name	
Sheet	1	Of	1
		Attorney Docket Number	02/104 DBA

U.S. PATENT DOCUMENTS							
Examiner Initials'	Cite No.	U. S. Patent Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Sub class
		2002/006773	A1	Patzke et al.	07/05/2001	435	2

FOREIGN PATENT DOCUMENTS									
Examiner Initials'	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	T6
		Office Number	Kind Code						
		WO	02/10437	A2	Blood Center Research Foundation	02/072002	C12Q	1/00	X
Examiner Signature					Date Considered				

IDS in WO rpt



PTO/SB/08A				Complete if Known	
Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application No.	10/519,824
				Filing Date	December 30, 2004
				First Named Inventor	Martina BOEHM
				Group Art Unit	
				Examiner Name	
Sheet	1	Of	1	Attorney Docket Number	02/0104 DBM

U.S. PATENT DOCUMENTS

Examiner Initials'	Cite No.	U. S. Patent Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Sub class

FOREIGN PATENT DOCUMENTS

Examiner Initials'	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	T6
		Office Number	Kind Code						
		WO	00/50904 = CA 2 362 483	A1	Baxter AG	02-23-2000	G01N	33/86	X
		WO	02/42441	A2	Baxter AG	05/30/2002	C12N	9/64	X
		EP	0 080 614 = US 4,563,431	A2	Behringwerke AG	06/08/1983	C08F	291/00	X
		EP	0 227 054 = CA 1,307,983	A2	Behringwerke AG	07/01/1987	C08F	257/02	X
		EP	0 246 446 = CA 1,292,683	A2	Behringwerke AG	11/25/1987	C08F	291/00	X
Examiner Signature					Date Considered				

IDS in spec

PTO/SB/08B				Completed <input checked="" type="checkbox"/> Known	
Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application No..	10/519,824
				Filing Date	December 30, 2004
				First Named Inventor	Martina BOEHM
				Group Art Unit	
				Examiner Name	Unknown
Sheet	1	Of	1	Attorney Docket Number	02/104 DBM
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials'	Cite No.	Include name of the author (in CAPITAL LETTERS), Title of the Article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T2		
		BOEHM, MARTINA M. et al.: "Von Willebrand Factor-cleaving protease activity in TTP using a new method based on the positive correlation between vWF multimeric size and Ristocetin Cofactor activity" BLOOD: Vol. 98, no. 11 Part 1, November 16, 2001, page 33a XP16. November 2001 (2001-11-16), pg. 33a, XP009022213; 43rd Annual Meeting of the American Society of Hematology, Part 1; Orlando, Florida, Dec. 07-11, 2001, ISSN: 0006-4971 Abstract	X		
		BOEHM, MARTINA M. et al.: "Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13)" ANNALS OF HERMATOLOGY: Vol. 81, no. 8, August 2002, pgs. 430-435, XP002263599; ISSN:0939-5555 (the whole document)	X		
		FURLAN MIHA et al.: "Assays of von Willebrand factor-cleaving protease: A test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura" SEMINARS IN THROMBOSIS AND HEMOSTASIS: Vol. 28, no. 2, April 2002, pgs. 167-172, XP009022244; ISSN: 0094-6176 (the whole document)	X		
		EWENSTEIN B. M.: "Use of ristocetin cofactor acativity in the management of von Willebrand disease" HAEMOPHILIA: THE OFFICIAL JOURNAL OF THE WORLD FEDERATION OF HEMOPHILIA; England; Vol. 7, Suppl 1, January 2000, pgs. 10-15, XP002263600; ISSN: 1351-8216 (the whole document)	X		
		KRIZEK DENNIS M et al: "Clinical application of a rapid method using agarose gel electrophoresis and Western blotting to evaluate von Willebrand factor protease activity" ELECTROPHORESIS Vol. 22, No. 5, March 2001, pgs. 946-949, XP002263601; ISSN: 0173-0835 (the whole document)	X		
		FURLAN MIHA: "von Willebrand factor: molecular size and functional activity" ANNALS OF HEMATOLOGY: Vol. 72, no. 6, 1996, pgs. 341-348, Berlin, Germany, XP000922763; ISSN: 0939-5555 (the whole document)	X		
EXAMINER			DATE CONSIDERED		
EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

PTO/SB/08B			Complete if Known.	
Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application No.	10/519,824
			Filing Date	December 30, 2004
			First Named Inventor	Martina BOEHM
			Group Art Unit	
			Examiner Name	Unknown
Sheet	1	Of	Attorney Docket Number	02/104 DBM

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials'	Cite No.	Include name of the author (in CAPITAL LETTERS), Title of the Article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T2
		Fujikawa, K., Suzuki, H., McMullen, B., Chung, D. (2001) Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98: 1662-1666.	X
		Gerritsen; H.E., Robles, R., Lämmele, B., Furlan, M. (2001) Partial amino acid sequence of purified von Willebrand factor-cleaving protease Blood 98: 1654-1661.	X
		Levy, G.G., Nichols, W.C., Lian, E.C. Foroud, T., McClintick, J.N., McGee, B.M., Yang, A.Y., Siemieniak, DR., Stark, K.R., Gruppo, R., Sarode, R., Shurin, S.B., Chandrasekaran, V., Stabler, S.P., Sabio, H., Bouhassira, E.E., Upshaw, J.D., Ginsburg, D., Tsai, H.M. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413: 488-494.	X
		Furlan, M., Robles, R., Lämmele, B., (1996) Partial purification and characterisation of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 10: 4223-4234.	X
		Tsai, H.M. (1996) Physiologic Cleavage of von Willebrand factor by a Plasma Protease is dependent on its confirmation and requires Calcium ion. Blood 10: 4235-4244.	X
		Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP (1999) Estimation of the Willebrand factor-cleaving protease in plasma using monoclonal antibodies to VWF. Thromb Haemost 82: 1382-1385	X
		Raife TJ, Atkinsons B, Christopherson P, Jozwiak M, Montgomery RR (2001) Recombinant, truncated monomeric von Willebrand factor (VWF) for the study of VWF proteolysis. Thromb Haemost, Suppl July: Abstract#1667	X
		Kasper, C.K. (1991) Laboratory tests for factor VIII inhibitors, their variation, significance and interpretation. Blood Coagul Fibrinolysis 2: 7-10.	X

EXAMINER

DATE CONSIDERED.

EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IDS in spec

PTO/SB/08B			Complete if Known	
Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application No..	10/519,824
			Filing Date	December 30, 2004
			First Named Inventor	Martina BOEHM
			Group Art Unit	
			Examiner Name	Unknown
Sheet	2	Of	Attorney Docket Number	02/104 DBM
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials'	Cite No.	Include name of the author (in CAPITAL LETTERS), Title of the Article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T2	
		BOEHM, MARTINA M. et al.: "Correlation of VWF-Cleaving Protease Activity, WF:AG and Frequency of Relapses in 17 TTP-Patients Observed Between 1982 and 2001"	X	
		(February , 2002) ZIM der J.W. Goethe University Fim (Frankfurt) abstract no. 28		
		BOEHM, MARTINA M. et al.: "The Significance of The VWF-Cleaving Protease in the Pathogenesis of TTP"	X	
		(February , 2002) ZIM der J.W. Goethe University Fim (Frankfurt) abstract no. 29		
EXAMINER			DATE CONSIDERED	
EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

IDS –additional ref